Skip to main content
SpringerLink
Log in

Prognostische und prädiktive Faktoren

  • Chapter
  • First Online:
Pathologie

Part of the book series: Pathologie ((PATHOL))

  • 5781 Accesses

Zusammenfassung

Das Kapitel stellt systematisch alle für die individuelle Prognose des Mammakarzinoms notwendigen sowie anerkannten Prognosefaktoren und prädiktiven Prognoseschemata, wie beispielsweise die TNM-Stadieneinteilung, das Nottingham-Grading-System oder den Nottingham Prognose-Index, vor. Zudem werden der Stand und die Bedeutung der gegenwärtig verfügbaren molekularen Signaturen besprochen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Albonico G, Querzoli P (1996) Biological heterogeneity of breast carcinoma in situ. Ann NY Acad Sci 784:458–461

    Article  PubMed  CAS  Google Scholar 

  2. Amat S, Penault-Llorca F, Cure H et al (2002) Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20:791–796

    PubMed  CAS  Google Scholar 

  3. Bässler R (1997) Histo- und zytomorphologisches Grading. In: Remmele W (ed) Pathologie 4. Springer, Berlin Heidelberg New York, pp 253–256

    Google Scholar 

  4. Bässler R (1997) Pathologie prognostischer Kriterien. In: Remmele W (ed) Pathologie – Weibliches Genitale. Mamma, Pathologie der Schwangerschaft, der Plazenta und des Neugeborenen, Infektionskrankheiten des Fetus und des Neugeborenen, Tumoren des Kindesalters, Endokrine Organe. vol. 4. Springer, Berlin Heidelberg New York, pp 240–253

    Google Scholar 

  5. Bettelheim R, Penman HG, Thornton-Jones H et al (1984) Prognostic significance of peritumoral vascular invasion in breast cancer. Br J Cancer 50:771–777

    Article  PubMed  CAS  Google Scholar 

  6. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377

    Article  PubMed  CAS  Google Scholar 

  7. Bogaerts J, Cardoso F, Buyse M et al (2006) Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3:540–551

    Article  PubMed  CAS  Google Scholar 

  8. Boiesen P, Bendahl PO, Anagnostaki L et al (2000) Histologic grading in breast cancer--reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 39:41–45

    Article  PubMed  CAS  Google Scholar 

  9. Buyse M, Loi S, van't Veer L et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192

    Article  PubMed  CAS  Google Scholar 

  10. Cardoso F, van't Veer L, Rutgers E et al (2008) Clinical Application of the 70-Gene Profile: The MINDACT Trial. J Clin Oncol 26:729–735

    Article  PubMed  Google Scholar 

  11. Chen LL, Nolan ME, Silverstein MJ et al (2009) The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. Cancer 115:5071–5083

    Article  PubMed  Google Scholar 

  12. Clemente CG, Boracchi P, Andreola S et al (1992) Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 69:1396–1403

    Article  PubMed  CAS  Google Scholar 

  13. Colozza M, Azambuja E, Cardoso F et al (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723–1739

    Article  PubMed  CAS  Google Scholar 

  14. Colozza M, Sidoni A, Piccart-Gebhart M (2010) Value of Ki67 in breast cancer: the debate is still open. Lancet Oncol 11:414–415

    Article  PubMed  Google Scholar 

  15. Cuzick J, Dowsett M, Pineda S et al (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 29:4273–4278

    Article  PubMed  Google Scholar 

  16. Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165

    Article  PubMed  CAS  Google Scholar 

  17. Dowsett M, Nielsen TO, A'Hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the international ki67 in breast cancer working group. J Natl Cancer Inst 103:1656–1664

    Article  PubMed  CAS  Google Scholar 

  18. Ein-Dor L, Zuk O, Domany E (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. PNAS 103:5923–5928

    Article  PubMed  CAS  Google Scholar 

  19. Ellis IO, Elston CW, Fletcher CD (1998) Tumours of the breast. Diagnostic histopathology of tumours. Churchill Livingstone, Edinburgh, pp 635–690

    Google Scholar 

  20. Fan C, Oh DS, Wessels L et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569

    Article  PubMed  CAS  Google Scholar 

  21. Filipits M, Rudas M, Jakesz R et al (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012–6020

    Article  PubMed  CAS  Google Scholar 

  22. Fitzgibbons PL, Page DL, Weaver D et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:966–978

    PubMed  CAS  Google Scholar 

  23. Frierson Jr HF, Wolber RA, Berean KW et al (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103:195–198

    PubMed  Google Scholar 

  24. Galea MH, Blamey RW, Elston CE et al (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:207–219

    Article  PubMed  CAS  Google Scholar 

  25. Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6:136–141

    Article  Google Scholar 

  26. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22:1736–1747

    Article  PubMed  CAS  Google Scholar 

  27. Gonzalez MA, Pinder SE (2011) Invasive carcinoma: Other histologic prognostic factors, prognostic indices, and application of prognostic information for partient management. In: O'Malley FP, Pinder SE, Mulligan AM (eds) Breast pathology. Elsevier, Philadelphia, pp 272–278

    Chapter  Google Scholar 

  28. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205

    PubMed  CAS  Google Scholar 

  29. Group EBCTC (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352:930–942

    Article  Google Scholar 

  30. Group EBCTC (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Article  Google Scholar 

  31. Group EBCTC (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  32. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–e72

    PubMed  CAS  Google Scholar 

  33. Harbeck N, Dettmar P, Thomssen C et al (1999) Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 80:419–426

    Article  PubMed  CAS  Google Scholar 

  34. Hayes DF, Bast RC, Desch CE et al (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456–1466

    Article  PubMed  CAS  Google Scholar 

  35. Hopton DS, Thorogood J, Clayden AD et al (1989) Observer variation in histological grading of breast cancer. Eur J Surg Oncol 15:21–23

    PubMed  CAS  Google Scholar 

  36. Hu Z, Fan C, Oh DS et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96

    Article  PubMed  Google Scholar 

  37. Jacquemier J, Charpin C (1998) Reproducibility of histoprognostic grades of invasive breast cancer. Ann Pathol 18:385–390

    PubMed  CAS  Google Scholar 

  38. Kelly CM, Krishnamurthy S, Bianchini G et al (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116:5161–5167

    Article  PubMed  Google Scholar 

  39. Robert-Koch-Institut (2010) Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. RKI, Berlin

    Google Scholar 

  40. Koscielny S (2008) Critical review of microarray-based prognostic tests and trials in breast cancer. Curr Opin Obstet Gynecol 20:47–50

    Article  PubMed  Google Scholar 

  41. Kuhn W, Schmalfeldt B, Reuning U et al (1999) Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79:1746–1751

    Article  PubMed  CAS  Google Scholar 

  42. Lauria R, Perrone F, Carlomagno C et al (1995) The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 76:1772–1778

    Article  PubMed  CAS  Google Scholar 

  43. Longacre TA, Ennis M, Quenneville LA et al (2006) Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19:195–207

    Article  PubMed  Google Scholar 

  44. Michaelson JS (2009) Technical Report #1-Mathematical Methods. http://www.lifemath.net/cancer/about/techreports/index.php

  45. Michaelson JS (2010) Technical Report #2-second Technical Report for the paper "CancerMath.net: Wed-based Calculators for Breast Carcinoma". http://www.lifemath.net/cancer/about/techreports/index.php

  46. Michaelson JS, Chen LL, Silverstein MJ et al (2009) How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. Cancer 115:5095–5107

    Article  PubMed  Google Scholar 

  47. Michiels S, Koscielny S, Hill C (2007) Interpretation of microarray data in cancer. Br J Cancer 96:1155–1158

    Article  PubMed  CAS  Google Scholar 

  48. O'Malley FP, Pinder SE (2006) Breast pathology. Churchill Livingstone, Elsevier, Philadelphia

    Google Scholar 

  49. Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12:631–635

    Article  PubMed  CAS  Google Scholar 

  50. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    Article  PubMed  CAS  Google Scholar 

  51. Parker JS, Mullins M, Cheang MCU et al (2009) Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol 27:1160–1167

    Article  PubMed  Google Scholar 

  52. Pauletti G, Dandekar S, Rong H et al (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664

    PubMed  CAS  Google Scholar 

  53. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26:1–10

    Article  PubMed  CAS  Google Scholar 

  54. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  PubMed  CAS  Google Scholar 

  55. Pinder SE, Ellis IO, Galea M et al (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24:41–47

    Article  PubMed  CAS  Google Scholar 

  56. Pockaj B, Wasif N, Dueck A et al (2010) Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer. Ann Surg Oncol 17:2419–2426

    Article  PubMed  Google Scholar 

  57. Rakha EA, El-Sayed ME, Lee AH et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158

    Article  PubMed  Google Scholar 

  58. Rakha EA, El-Sayed ME, Menon S et al (2008) Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 111:121–127

    Article  PubMed  Google Scholar 

  59. Regitnig P, Reiner A, Dinges HP et al (2002) Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch 441:328–334

    Article  PubMed  CAS  Google Scholar 

  60. Robbins P, Pinder S, de Klerk N et al (1995) Histological grading of breast carcinomas: a study of interobserver agreement. Human Pathol 26:873–879

    Article  CAS  Google Scholar 

  61. Scharl A (2011) Aktuelle Empfehlungen zur Prävention, Diagnostik und Therapie primärer und fortgeschrittener Mammakarzinome. Zuckschwerdt, München

    Google Scholar 

  62. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322

    Article  PubMed  CAS  Google Scholar 

  63. Schumacher M, Schmoor C, Sauerbrei W et al (1993) The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 25:235–245

    Article  PubMed  CAS  Google Scholar 

  64. Sloane JP, Amendoeira I, Apostolikas N et al (1999) Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 434:3–10

    Article  PubMed  CAS  Google Scholar 

  65. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874

    Article  PubMed  CAS  Google Scholar 

  66. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423

    Article  PubMed  CAS  Google Scholar 

  67. Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272

    Article  PubMed  CAS  Google Scholar 

  68. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347–350

    Article  PubMed  Google Scholar 

  69. Surveillance Epidemiology and End Results (SEER) Program (2010) National Cancer Institute. Bethesda, MD. SEER Cancer Statistics Review, 1975–2008, based on November 2010 SEER data submission, posted to the SEER web site, 2011. In: Howlader N et al. (eds) http://www.seer.cancer.gov/csr/1975_2008/

  70. Theissig F, Kunze KD, Haroske G et al (1990) Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract 186:732–736

    Article  PubMed  CAS  Google Scholar 

  71. Tot T (2007) Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections. Cancer 110:2551–2560

    Article  PubMed  Google Scholar 

  72. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220

    Article  PubMed  CAS  Google Scholar 

  73. van de Vijver MJ, He YD, van't Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009

    Article  PubMed  Google Scholar 

  74. Wang Y, Klijn JG, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679

    PubMed  CAS  Google Scholar 

  75. Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220:263–280

    Article  PubMed  CAS  Google Scholar 

  76. Weigelt B, Mackay A, A'Hern R et al (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11:339–349

    Article  PubMed  CAS  Google Scholar 

  77. Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65

    Article  PubMed  Google Scholar 

  78. Wittekind C, Meyer HJ (2010) TNM Klassifikation maligner Tumoren. Wiley-VCH, Weinheim

    Google Scholar 

  79. Woodward WA, Strom EA, Tucker SL et al (2003) Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival. J Clin Oncol 21:3244–3248

    Article  PubMed  Google Scholar 

  80. Yerushalmi R, Woods R, Ravdin PM et al (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11:174–183

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Thomas Decker Dr.

    Present address: Institut für Pathologie, Dietrich-Bonhoeffer-Klinikum, Salvador-Allende Str.30, 17036, Neubrandenburg-Oststadt, Deutschland

  2. Werner Böcker Prof. em. Dr. med.

    Present address: Referenz- und Konsultationszentrum für Gynäko- und Mammapathologie, Fangdieckstr. 75a, 22547, Hamburg, Deutschland

Authors and Affiliations

  1. Gerhard Domagk Institut für Pathologie der Universität Münster, Münster, Deutschland

    Werner Böcker Prof. em. Dr. med.

Authors
  1. Thomas Decker Dr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Böcker Prof. em. Dr. med.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Werner Böcker Prof. em. Dr. med. .

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Konsultationszentrum für Pankreas- und, TU München, Ismaninger Str. 22, München, 81675, Germany

    Günter Klöppel

  2. Inst. Pathologie, Medizinische Hochschule Hannover (MHH), Carl-Neuberg-Str. 1, Hannover, 30623, Germany

    Hans Kreipe

  3. Kliniken der Landeshauptstadt, Institut für Pathologie, Ludwig-Erhard-Straße 100, Wiesbaden, 65199, Germany

    Wolfgang Remmele

  4. Charite - Universitätsmedizin Berlin, Campus Charité Mitte, Institut für Pathologie, Charitéplatz 1, Berlin, 10117, Berlin, Germany

    Manfred Dietel

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Decker, T., Böcker, W. (2013). Prognostische und prädiktive Faktoren. In: Klöppel, G., Kreipe, H., Remmele, W., Dietel, M. (eds) Pathologie. Pathologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04564-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04564-6_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04563-9

  • Online ISBN: 978-3-642-04564-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation